Research Topics
| Howard BaileySummaryAffiliation: University of Wisconsin Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancerHoward H Bailey
University of Wisconsin Paul P Carbone Cancer Center, Madison, USA
Cancer Prev Res (Phila) 3:35-47. 2010..069) in new NMSC that was predominantly due to a marked reduction in new BCC. Based on these data, the potential of DFMO, alone or in combination, to prevent skin cancers should be explored further...
Phase II study of daily oral perifosine in patients with advanced soft tissue sarcomaHoward H Bailey
University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
Cancer 107:2462-7. 2006....- Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumorsHoward H Bailey
University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
Clin Cancer Res 13:3623-9. 2007..To assess the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacodynamics, and antitumor activity of continuous weekly-administered paclitaxel and BMS-214662, a novel farnesyl transferase inhibitor... - A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinomaSherry Morgan-Meadows
University of Wisconsin Comprehensive Cancer Center, Madison, WI 53792, USA
Oncology 69:130-4. 2005..The aim of this study was to evaluate the overall response rate, toxicity and overall survival in patients with locally advanced or metastatic esophageal cancer treated with gemcitabine, 5-fluorouracil (5-FU) and leucovorin... - Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancerGlenn Liu
University of Wisconsin Comprehensive Cancer Center, Madison, WI 53792, USA
Invest New Drugs 21:367-72. 2003..CONCLUSION: Perillyl alcohol administered at this dose and formulation did not have any objective clinical activity in this patient population... 
A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumorsWilliam Schelman
University of Wisconsin Paul P Carbone Comprehensive Cancer Center, 600 Highland Avenue, K4 530 CSC, Madison, WI 53792, USA
Cancer Chemother Pharmacol 62:727-33. 2008..We conducted a phase I trial to assess the maximum tolerated dose, dose limiting toxicity (DLT) and antitumor activity of gemcitabine and patupilone...- Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation designAmye Tevaarwerk
University of Wisconsin Carbone Cancer Center, Madison, WI, USA
Invest New Drugs 30:1039-45. 2012..The primary objectives were to determine the maximum tolerated dose (MTD) and response of continuous MKC-1. Secondary objectives included characterizing the dose limiting toxicities (DLTs) and pharmacokinetics (PK)... - Phase I trial of perillyl alcohol administered four times daily continuouslySherry Morgan-Meadows
University of Wisconsin Comprehensive Cancer Center, 600 Highland Ave K4 601, Madison, Wisconsin 53792, USA
Cancer Chemother Pharmacol 52:361-6. 2003..Therefore, a new formulation of POH was developed (700 mg containing 675 mg POH) in an effort to improve dose and metabolite concentrations delivered and toxicity encountered with chronic dosing... - Phase II trial of perillyl alcohol in patients with metastatic colorectal cancerSherry Morgan Meadows
Department of Medicine, Division of Medical Oncology, The University of Wisconsin, Madison, WI, USA
Int J Gastrointest Cancer 32:125-8. 2002..This is a phase II study of perillyl alcohol in the treatment of patients with metastatic colorectal carcinoma. The primary endpoint is time to progression. Secondary objectives are to evaluate objective response rate and toxicity... - The Wisconsin Network for Health Research (WiNHR): a statewide, collaborative, multi-disciplinary, research groupHoward Bailey
University of Wisconsin School of Medicine and Public Health, Madison 53792, USA
WMJ 108:453-8. 2009..This optimism is based on the relevance of its goals to public health, the quality of statewide health care research, and, most importantly, the residents of Wisconsin who recognize the value of health research... - The differential diagnosis of pulmonary blastomycosis using case vignettes: a Wisconsin Network for Health Research (WiNHR) studyDennis J Baumgardner
Department of Family Medicine, University of Wisconsin School of Medicine and Public Health, Milwaukee, USA
WMJ 110:68-73. 2011..This study addressed the diagnostic accuracy of physicians responding to case vignettes of pulmonary blastomycosis and the primary care differential diagnosis of this disease... - A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer: Eastern Cooperative Oncology Group Study E2E96Howard H Bailey
University of Wisconsin Madison, Madison, Wisconsin 53792, USA
Gynecol Oncol 85:464-8. 2002..Perillyl alcohol was administered orally, four times daily, at a dose of 1200 mg/m(2). This was repeated until disease progression or unacceptable toxicity was experienced... - Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignanciesAnne M Traynor
University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, WI 53792, USA
Invest New Drugs 29:316-22. 2011..To assess the safety, maximum-tolerated dose (MTD), and dose-limiting toxicities (DLT), of motexafin gadolinium (MGd), given in combination with doxorubicin, in patients with advanced solid tumors... - Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignanciesSteven Attia
University of Wisconsin Paul P Carbone Comprehensive Cancer Center Madison, Madison, WI 53792, USA
Cancer Chemother Pharmacol 64:45-51. 2009..To define dose limiting toxicities (DLTs) and the maximum tolerated dose (MTD) of capecitabine with fixed-dose rate (FDR) gemcitabine... - Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridolJames P Thomas
University of Wisconsin Comprehensive Cancer Center, University of Wisconsin Medical School, 600 Highland Ave, Madison, WI 53792, USA
Cancer Chemother Pharmacol 50:465-72. 2002..The manageable gastrointestinal toxicity, early signs of clinical activity and lack of hematologic toxicity make further exploration in combination trials warranted... - Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancerHoward H Bailey
University of Wisconsin Paul P Carbone Comprehensive Cancer Center, 600 Highland Avenue K4 6 CSC, Madison, WI 53792, USA
Cancer Chemother Pharmacol 62:149-57. 2008..We conducted a phase II multi-institutional study of oral POH administered four times daily in women with advanced treatment-refractory breast cancer... - Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trialDavid M Kushner
Division of Gynecologic Oncology, University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, and Regional Cancer Center at Oconomowoc Waukesha Memorial Hospitals, WI, USA
Gynecol Oncol 105:358-64. 2007..The optimal specific combination has yet to be determined. The current study evaluates weekly docetaxel and carboplatin in this setting... - Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network StudyBrad S Kahl
Department of Medicine, University of Wisconsin Comprehensive Cancer Center, University of Wisconsin Medical School, Madison, WI 53792, USA
Cancer Invest 23:13-8. 2005..The response rate appears similar to other reports using different doses and schedules. Myelosuppression appears less with this schedule than with other schedules... - A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 daysHoward H Bailey
University of Wisconsin Comprehensive Cancer Center, K6 568 CSC, 600 Highland Avenue, Madison, WI 53792 5669, USA
Cancer Chemother Pharmacol 54:368-76. 2004..A phase I study of POH for 14 days out of every 28 days in subjects with advanced malignancies was performed to evaluate dose escalation, toxicity, pharmacokinetics, and effects on TGFbeta and Ras... - Gemcitabine, Paclitaxel, and piritrexim: a phase I studyGlenn Liu
University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, USA
Am J Clin Oncol 26:280-4. 2003..The combination of these new antifolates with paclitaxel and gemcitabine appears safe and should be considered for phase II trials in known responsive tumors such as transitional cell carcinomas... - Phase II study of doxercalciferol for the treatment of myelodysplastic syndromeAdam Petrich
Department of Medicine, University of Wisconsin Comprehensive Cancer Center, University of Wisconsin, Madison, WI, USA
Leuk Lymphoma 49:57-61. 2008..Overall the treatment was well tolerated. One patient was removed from study due to hypercalcemia. We conclude that short-term treatment with doxercalciferol has limited activity in patients with MDS... - Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancySherry Morgan-Meadows
University of Wisconsin Comprehensive Cancer Center, Madison 53792, USA
Invest New Drugs 20:377-82. 2002..The objectives of this trial were to assess the maximal tolerated dose and toxicity of the combination of oral eniluracil and 5-fluorouracil and intravenous gemcitabine... - Progress of a Comprehensive Familial Cancer Genetic Counseling Program in the Era of BRCA1 and BRCA2Ellen M Hartenbach
University of Wisconsin Comprehensive Cancer Center, Gynecologic Oncology Program, Madison 53792, USA
Genet Test 6:75-8. 2002..In our program, the majority of families counseled were eligible for BRCA1/BRCA2 testing, but only 18% have elected to proceed at this time... - Non-Hodgkin's lymphoma presenting as a pelvic mass with elevated CA-125Gregory W Allen
Department of Human Oncology, University of Wisconsin Hospital and Clinics, Madison, WI 53792, USA
Gynecol Oncol 94:811-3. 2004..While ovarian cancer is high on the list of differential diagnoses, lymphoma cannot be excluded until a tissue diagnosis is obtained... - Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancerGlenn Liu
University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
Clin Cancer Res 8:2820-7. 2002..Whereas the defined maximum tolerated dose was not reached, the recommended Phase II dose was 12.5 microg/day given continuously... - Phase II study of 1alpha-hydroxyvitamin D(2) in the treatment of advanced androgen-independent prostate cancerGlenn Liu
Department of Medicine, Medical Oncology Section, University of Wisconsin Comprehensive Cancer Center, 600 Highland Avenue, Madison, WI 53792, USA
Clin Cancer Res 9:4077-83. 2003..CONCLUSION: The results of this and other trials suggest further clinical investigation in this disease with vitamin D analogues alone or in combination with other agents, such as chemotherapy, should be pursued... - A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group studyDeborah K Armstrong
John Hopkins Kimmel Cancer Center, Bunting Blaustein Cancer Research Building, Baltimore, MD 21231 1000, USA
Gynecol Oncol 103:391-6. 2006..The goals of this phase I study were to determine the maximum tolerated dose (MTD) of IP paclitaxel microspheres and the pharmacology of paclitaxel after IP paclitaxel microsphere administration...
Research Grants
- Chemoprevention of Skin Cancer - DFMO Phase III TrialHoward Bailey; Fiscal Year: 2005..Ototoxicity and gastrointestinal toxicity have been most common). The objectives, which are unchanged from our original proposal, are all on schedule to be completed in the next 1-2 years. ..
- DFMO Prevention Study (2b) in Organ Transplant SubjectsHoward Bailey; Fiscal Year: 2005..abstract_text> ..